 Entera Bio Ltd. ENTX the Company or Entera, a global innovator in drug delivery platforms, announced today that it increased the size of and completed its previously announced private placement offering the Offering with a select group of accredited investors the Purchasers, bringing the anticipated aggregate gross proceeds to 14.3 million from the sale of an aggregate of 6,047,693 ordinary shares, par value NIS 0.0000769 per share the Shares at a price of 2.37 per share. In addition, as part of the offering, the Company has granted the Purchasers and certain finders an aggregate of 3,300,637 three-year warrants to purchase up to an additional 3,300,637 ordinary shares at an exercise price between 2.37 and 2.96 per share the Warrants and together with the Shares, the Securities. 